- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1528-3658
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Novel targeted therapies for Parkinson’s disease ; volume:27 ; number:1 ; day:25 ; month:2 ; year:2021 ; pages:1-20 ; date:12.2021
Molecular medicine ; 27, Heft 1 (25.2.2021), 1-20, 12.2021
- Urheber
-
Ntetsika, Theodora
Papathoma, Paraskevi-Evita
Markaki, Ioanna
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s10020-021-00279-2
- URN
-
urn:nbn:de:101:1-2021042220265466656360
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:52 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Ntetsika, Theodora
- Papathoma, Paraskevi-Evita
- Markaki, Ioanna
- SpringerLink (Online service)
Ähnliche Objekte (12)
Current and novel infusion therapies for patients with Parkinson's disease
ROS networks: designs, aging, Parkinson’s disease and precision therapies
Novel gene (TMEM230) linked to Parkinson’s disease
Advanced therapies in Parkinson’s disease: an individualized approach to their indication
Advanced therapies in Parkinson’s disease: an individualized approach to their indication
Gene and Cell-Based Therapies for Parkinson’s Disease: Where Are We?
Novel biomarkers and neuroimaging techniques in Parkinson’s disease
Non-oral continuous drug delivery based therapies and sleep dysfunction in Parkinson’s disease
Targeted degradation of ⍺-synuclein aggregates in Parkinson’s disease using the AUTOTAC technology
Precision medicine in Parkinson’s disease: emerging treatments for genetic Parkinson’s disease
Nutraceuticals in Parkinson’s Disease
Redefinition of Parkinson’s Disease
Current and novel infusion therapies for patients with Parkinson's disease
ROS networks: designs, aging, Parkinson’s disease and precision therapies
Novel gene (TMEM230) linked to Parkinson’s disease
Advanced therapies in Parkinson’s disease: an individualized approach to their indication
Advanced therapies in Parkinson’s disease: an individualized approach to their indication
Gene and Cell-Based Therapies for Parkinson’s Disease: Where Are We?
Novel biomarkers and neuroimaging techniques in Parkinson’s disease
Non-oral continuous drug delivery based therapies and sleep dysfunction in Parkinson’s disease
Targeted degradation of ⍺-synuclein aggregates in Parkinson’s disease using the AUTOTAC technology
Precision medicine in Parkinson’s disease: emerging treatments for genetic Parkinson’s disease
Nutraceuticals in Parkinson’s Disease
Redefinition of Parkinson’s Disease
Current and novel infusion therapies for patients with Parkinson's disease
ROS networks: designs, aging, Parkinson’s disease and precision therapies
Novel gene (TMEM230) linked to Parkinson’s disease
Advanced therapies in Parkinson’s disease: an individualized approach to their indication
Advanced therapies in Parkinson’s disease: an individualized approach to their indication
Gene and Cell-Based Therapies for Parkinson’s Disease: Where Are We?
Novel biomarkers and neuroimaging techniques in Parkinson’s disease
Non-oral continuous drug delivery based therapies and sleep dysfunction in Parkinson’s disease
Targeted degradation of ⍺-synuclein aggregates in Parkinson’s disease using the AUTOTAC technology
Precision medicine in Parkinson’s disease: emerging treatments for genetic Parkinson’s disease
Nutraceuticals in Parkinson’s Disease